PATENT CLAIM ANALYSIS

Application Number: 16229252
Application Type: Utility
Filing Date: 2018-12
Publication Date: 2019-04
Patent Classification: ["128", "848000"]

Abstract:
A method for reducing the likelihood of developing non-alcoholic steatohepatitis (NASH) in an individual diagnosed with non-alcoholic fatty liver disease involves providing in the gut of an individual a population of beneficial bacteria selected from the group consisting of  Lactobacillus  species, and at least 6 grams per day of fiber to the individual to maintain a therapeutically effective amount of the beneficial bacteria in the gut of the individual. In certain embodiments, monoacylglycerolacyltransferase-3 (MGAT3) synthesis is inhibited to lower triacylglycerol (TAG) production, while in others, expression of diacylglycerolacyltransferase-2 (DGAT-2) is inhibited. The beneficial bacteria are preferably modified to produce increased amounts of butyrate and are also encapsulated in a frangible enclosure. Levels of  Roseburia  are preferably increased while the levels of  Akkermansia  spp. in the individual's gut microbiome are reduced.

Claim (Index 4):
The method as set forth in  claim 1 , further comprising inhibiting expression of diacylglycerolacyltransferase-2 (DGAT-2) in said individual.

Metadata:
- Claim Count in Document: 11.0
- Percentile: 98.0
- Lexical Diversity: 1.72093
- Patent Class: 128.0
- Transitional Phrase Type: open
- Component Type: 1
- Foreign Priority: False
- Related Applications: ['15392173', '16142171', '15395419', '16160336', '15983250']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.6901590585661191
- 35 USC 102 Novelty (BERT): 0.6677173580221203
- Combined Prediction Score: 0.6879148885117193
- Mean Citation Score: 346.774848
- Max Citation Score: 565.7197
- Similarity Product: 543.380786589551

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test